Conclusion: Improvements in treatment strategies during the last 25 years have resulted in
lower disease activity, less mortality, more DFR and better physical functioning of RA …

Background Fenebrutinib (GDC-0853, FEN) is a small molecule inhibitor of Bruton's
Tyrosine Kinase (BTK) that is orally administered, highly selective, non-covalent, and …

Background: Overall, fenebrutinib has been well tolerated, with mostly non-serious AEs, mild-
to-moderate in naturea aRoche data on file; bMay affect the efficacy of fenebrutinib, or lead …

Objective: To compare the safety and tolerability of fenebrutinib in people with multiple
sclerosis (MS) and those with autoimmune indications (AIs). Background: Fenebrutinib is a …

The Safety Profile of Fenebrutinib in Patients With Multiple Sclerosis Is Consistent With Those In
Previously Studied Autoimmune Page 1 The Safety Profile of Fenebrutinib in Patients With …

Background: Bruton tyrosine kinase (BTK) is a validated target in CLL. Ibrutinib is a BTK
inhibitor that has dramatically improved progression-free survival (PFS) and overall survival …

Objective: To analyze the large fenebrutinib safety database of prior autoimmune
randomized clinical trials (RCTs) and open-label extensions (OLEs). Background …

Background: Fenebrutinib (GDC-0853, FEN) is a non-covalent, oral, and highly selective
inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of …

Ibrutinib-based therapies are costly and require continuous administration. We hypothesized
combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep …

Mazyar Shadman,1 Ian W. Flinn,2 Edwin C. Kingsley,3 Benjamin Freeman,4 Moshe Y. Levy,5
Houston Holmes,5 Charles M. F Page 1 CONCLUSIONS ■ With a median zanubrutinib …